ArticleOsteoarthritis and cartilage2017
Role of the C-C chemokine receptor-2 in a murine model of injury-induced osteoarthritis.
Article in Osteoarthritis and cartilage, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 70 citations in OpenAlex.
- Sustained release of exogeneous fetuin-A from Hyaluronic acid microplates decreases joint degeneration, synovial hyperplasia and muscle damage in a murine post-traumatic osteoarthritis model.Arthritis research & therapy · 2025Article
- Pharmacological antagonism of Ccr2+ cell recruitment to facilitate regenerative tendon healing.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025Article
- Neuro-Immunomodulatory Potential of Nanoenabled 4D Bioprinted Microtissue for Cartilage Tissue Engineering.Advanced healthcare materials · 2025Article
- Dietary supplementation of vitamin B1 prevents the pathogenesis of osteoarthritis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Pharmacological Antagonism of Ccr2+ Cell Recruitment to Facilitate Regenerative Tendon Healing.bioRxiv : the preprint server for biology · 2024Article
- Aging and the emerging role of cellular senescence in osteoarthritis.Osteoarthritis and cartilage · 2024Review
- Molecular pathogenesis of OA pain: Past, present, and future.Osteoarthritis and cartilage · 2024Review
- CC Chemokine Family Members' Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury-A Review of Clinical and Experimental Findings.International journal of molecular sciences · 2024Review
- Essential role of the CCL2-CCR2 axis in Mayaro virus-induced disease.Journal of virology · 2024Article
- Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues.Frontiers in immunology · 2024Review
- TLR4 antagonism provides short-term but not long-term clinical benefit in a full-depth cartilage defect mouse model.Connective tissue research · 2024Article
- Age-Associated Changes in Knee Osteoarthritis, Pain-Related Behaviors, and Dorsal Root Ganglia Immunophenotyping of Male and Female Mice.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain.Molecules (Basel, Switzerland) · 2023Review
- CC chemokines and receptors in osteoarthritis: new insights and potential targets.Arthritis research & therapy · 2023Review
- The gut microbiota metabolite capsiate regulate SLC2A1 expression by targeting HIF-1α to inhibit knee osteoarthritis-induced ferroptosis.Aging cell · 2023Article
- CC-Chemokine Receptor-2 Expression in Osteoblasts Contributes to Cartilage and Bone Damage during Post-Traumatic Osteoarthritis.Biomolecules · 2023Article
- CCL12 induces trabecular bone loss by stimulating RANKL production in BMSCs during acute lung injury.Experimental & molecular medicine · 2023Article
- Sustained inhibition of CC-chemokine receptor-2 via intraarticular deposition of polymeric microplates in post-traumatic osteoarthritis.Drug delivery and translational research · 2023Article
- Experimental models to study osteoarthritis pain and develop therapeutics.Osteoarthritis and cartilage open · 2022Review
- Early ablation of Ccr2 in aggrecan-expressing cells following knee injury ameliorates joint damage and pain during post-traumatic osteoarthritis.Osteoarthritis and cartilage · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
Abstract
objectiveWe previously found in our embryonic studies that proper regulation of the chemokine CCL12 through its sole receptor CCR2, is critical for joint and growth plate development. In the present study, we examined the role of CCR2 in injury-induced-osteoarthritis (OA).
methodWe used a murine model of injury-induced-OA (destabilization of medial meniscus, DMM), and systemically blocked CCR2 using a specific antagonist (RS504393) at different times during disease progression. We examined joint degeneration by assessing cartilage (cartilage loss, chondrocyte hypertrophy, MMP-13 expression) and bone lesions (bone sclerosis, osteophytes formation) with or without the CCR2 antagonist. We also performed pain behavioral studies by assessing the weight distribution between the normal and arthritic hind paws using the IITS incapacitance meter.
resultsTesting early vs delayed administration of the CCR2 antagonist demonstrated differential effects on joint damage. We found that OA changes in articular cartilage and bone were ameliorated by pharmacological CCR2 blockade, if given early in OA development: specifically, pharmacological targeting of CCR2 during the first 4 weeks (wks) following injury, reduced OA cartilage and bone damage, with less effectiveness with later treatments. Importantly, our pain-related behavioral studies showed that blockade of CCR2 signaling during early, 1-4 wks post-surgery or moderate, 4-8 wks post-surgery, OA was sufficient to decrease pain measures, with sustained improvement at later stages, after treatment was stopped.
conclusionsOur data highlight the potential efficacy of antagonizing CCR2 at early stages to slow the progression of post-injury OA and, in addition, improve pain symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.